Retour

Jasper Therapeutics to Present at Upcoming Investor Conferences in May

Calendar Calendar of Events

REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the following upcoming investor conferences in May:

GlobeNewswire Inc. • 07/05/2024 à 22:30:00
Jasper Therapeutics, Inc. Common Stock
Address: 2200 BRIDGE PKWY SUITE #102
Postal Code: 94065
City: REDWOOD CITY
State: CA
Phone Number: (650) 549-1400
Website: https://www.jaspertherapeutics.com
Status: Active
Company Info

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

List Date2021-09-27
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001788028
Composite figiBBG00QPZNP97
Share Class figiBBG00QPZNPB4
Market Cap347,269,430 USD
SIC Code2836
SIC DescriptionBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Total Employees45
Share Class Shares Outstanding15090000
Weighted Shares Outstanding15085553
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
23.03
23.794
21.436
20.95
20.785
Variance
-2.68%
11.12%
2.8%
0.79%
-2.39%
Open
23.664
21.413
20.852
20.785
21.295
Highest
23.755
23.794
21.675
21.685
22.299
Lowest
23.714
23.041
21.595
21.685
22.041
History
PeriodVarhighestlowest
1 week
8.15%
22.299
21.595
1 month
10.67%
23.23
21.56
3 month
2.4%
22.49
19.74
6 month
260.01%
6.5
4
1 year
27.94%
18.5
4
3 year
-83.62%
149
3.862
5 year
-83.62%
149
3.862
10 year
-83.62%
149
3.862
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-12 2023-08-11 2023-11-09 UNPUB
Assets 138,757,000 124,170,000 110,405,000 UNPUB
Current Assets 132,508,000 118,567,000 105,218,000 UNPUB
Current Liabilities 7,892,000 8,972,000 11,906,000 UNPUB
Equity 125,198,000 110,205,000 94,133,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 125,198,000 110,205,000 94,133,000 UNPUB
Liabilities 13,559,000 13,965,000 16,272,000 UNPUB
Liabilities And Equity 138,757,000 124,170,000 110,405,000 UNPUB
Noncurrent Assets 6,249,000 5,603,000 5,187,000 UNPUB
Noncurrent Liabilities 5,667,000 4,993,000 4,366,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-12 2023-08-11 2023-11-09 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 91,150,000 -13,588,000 -11,945,000 UNPUB
Net Cash Flow, Continuing 91,150,000 -13,588,000 -11,945,000 UNPUB
Net Cash Flow From Financing Activities 101,511,000 -305,000 36,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 101,511,000 -305,000 36,000 UNPUB
Net Cash Flow From Investing Activities -26,000 -11,000 0 UNPUB
Net Cash Flow From Investing Activities, Continuing -26,000 -11,000 0 UNPUB
Net Cash Flow From Operating Activities -10,335,000 -13,272,000 -11,981,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -10,335,000 -13,272,000 -11,981,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-12 2023-08-11 2023-11-09 UNPUB
Comprehensive Income/Loss -14,260,000 16,100,000 -17,544,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -14,260,000 16,100,000 -17,544,000 UNPUB
Other Comprehensive Income/Loss 0 0 0 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-12 2023-08-11 2023-11-09 UNPUB
Basic Earnings Per Share 0 0 0 UNPUB
Benefits Costs and Expenses 0 -16,209,000 0 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 13,877,000 -16,209,000 19,413,000 UNPUB
Diluted Earnings Per Share 0 0 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -14,260,000 16,100,000 -17,544,000 UNPUB
Income/Loss From Continuing Operations Before Tax -70,000 16,100,000 51,000 UNPUB
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -14,260,000 16,100,000 -17,544,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 32,180,000 0 UNPUB
Net Income/Loss Attributable To Parent -14,260,000 -16,080,000 -17,544,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -14,260,000 -16,080,000 -17,544,000 UNPUB
Operating Expenses 13,947,000 17,827,000 19,362,000 UNPUB
Operating Income/Loss -13,947,000 -17,827,000 -19,362,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues -70,000 -109,000 51,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 2022-08-12 2022-11-10 2023-03-08
Assets 80,548,000 70,366,000 59,110,000 48,361,000
Current Assets 73,799,000 63,286,000 52,411,000 41,731,000
Current Liabilities 5,969,000 6,622,000 7,421,000 7,065,000
Equity 68,105,000 58,781,000 47,565,000 35,989,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 68,105,000 58,781,000 47,565,000 35,989,000
Liabilities 12,443,000 11,585,000 11,545,000 12,372,000
Liabilities And Equity 80,548,000 70,366,000 59,110,000 48,361,000
Noncurrent Assets 6,749,000 7,080,000 6,699,000 6,630,000
Noncurrent Liabilities 0 0 4,124,000 5,307,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 2022-08-12 2022-11-10 2023-03-08
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow -14,229,000 -9,586,000 -9,864,000 -46,379,000
Net Cash Flow, Continuing -14,229,000 -9,586,000 -9,864,000 -46,379,000
Net Cash Flow From Financing Activities 13,000 13,000 1,000 55,000
Net Cash Flow From Financing Activities, Continuing 13,000 13,000 1,000 55,000
Net Cash Flow From Investing Activities -29,000 -243,000 -222,000 -576,000
Net Cash Flow From Investing Activities, Continuing -29,000 -243,000 -222,000 -576,000
Net Cash Flow From Operating Activities -14,213,000 -9,356,000 -9,643,000 -45,858,000
Net Cash Flow From Operating Activities, Continuing -14,213,000 -9,356,000 -9,643,000 -45,858,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 2022-08-12 2022-11-10 2023-03-08
Comprehensive Income/Loss -2,207,000 -10,404,000 -11,863,000 37,700,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -2,207,000 -10,404,000 -11,863,000 37,700,000
Other Comprehensive Income/Loss 0 0 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-12 2022-08-12 2022-11-10 2023-03-08
Basic Earnings Per Share UNPUB UNPUB 0 -1
Benefits Costs and Expenses 2,135,000 0 0 UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 2,135,000 12,052,000 12,976,000 UNPUB
Diluted Earnings Per Share UNPUB UNPUB 0 -1
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -2,207,000 -10,404,000 -11,863,000 37,700,000
Income/Loss From Continuing Operations Before Tax -2,207,000 -10,404,000 268,000 37,700,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -2,207,000 -10,404,000 -11,863,000 37,700,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 75,385,000
Net Income/Loss Attributable To Parent -2,207,000 -10,404,000 -11,863,000 -37,685,000
Net Income/Loss Available To Common Stockholders, Basic -2,207,000 -10,404,000 -11,863,000 -37,685,000
Operating Expenses 12,778,000 11,963,000 12,708,000 51,196,000
Operating Income/Loss -12,778,000 -11,963,000 -12,708,000 -51,196,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues -72,000 89,000 268,000 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-12 2022-03-18
Assets UNPUB UNPUB 107,213,000 93,654,000
Current Assets UNPUB UNPUB 102,407,000 87,831,000
Current Liabilities UNPUB UNPUB 9,159,000 8,020,000
Equity UNPUB UNPUB 78,602,000 69,518,000
Equity Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Equity Attributable To Parent UNPUB UNPUB 78,602,000 69,518,000
Liabilities UNPUB UNPUB 28,611,000 24,136,000
Liabilities And Equity UNPUB UNPUB 107,213,000 93,654,000
Noncurrent Assets UNPUB UNPUB 4,806,000 5,823,000
Noncurrent Liabilities UNPUB UNPUB 19,452,000 16,116,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-12 2022-03-18
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB UNPUB 81,067,000 64,863,000
Net Cash Flow, Continuing UNPUB UNPUB 81,067,000 64,863,000
Net Cash Flow From Financing Activities UNPUB UNPUB 101,417,616 100,969,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB 101,417,616 100,969,000
Net Cash Flow From Investing Activities UNPUB UNPUB -1,935,242 -2,428,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB -1,935,242 -2,428,000
Net Cash Flow From Operating Activities UNPUB UNPUB -18,415,374 -33,678,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB -18,415,374 -33,678,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-12 2022-03-18
Comprehensive Income/Loss UNPUB UNPUB -3,412,000 -30,637,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB -3,412,000 -30,637,000
Other Comprehensive Income/Loss UNPUB UNPUB 0 0
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2021-11-12 2022-03-18
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB 3,403,000 30,557,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB 3,403,000 30,557,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB UNPUB -3,412,000 -30,637,000
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB -3,412,000 -30,637,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB UNPUB -3,412,000 -30,637,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Net Income/Loss Attributable To Parent UNPUB UNPUB -3,412,000 -30,637,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB -3,412,000 -30,637,000
Operating Expenses UNPUB UNPUB 10,079,000 36,833,000
Operating Income/Loss UNPUB UNPUB -10,079,000 -36,833,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB 0 0
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB 0 0
Revenues UNPUB UNPUB -9,000 -80,000
Calendar
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:JSPR240517P00040000 OPASPS Put American 100 40 BATO 2024-05-17
O:JSPR240517P00035000 OPASPS Put American 100 35 BATO 2024-05-17
O:JSPR240517P00030000 OPASPS Put American 100 30 BATO 2024-05-17
O:JSPR240517P00025000 OPASPS Put American 100 25 BATO 2024-05-17
O:JSPR240517P00022500 OPASPS Put American 100 22.5 BATO 2024-05-17
O:JSPR240517P00020000 OPASPS Put American 100 20 BATO 2024-05-17
O:JSPR240517P00017500 OPASPS Put American 100 17.5 BATO 2024-05-17
O:JSPR240517P00015000 OPASPS Put American 100 15 BATO 2024-05-17
O:JSPR240517P00012500 OPASPS Put American 100 12.5 BATO 2024-05-17
O:JSPR240517C00040000 OCASPS Call American 100 40 BATO 2024-05-17
O:JSPR240517C00035000 OCASPS Call American 100 35 BATO 2024-05-17
O:JSPR240517C00030000 OCASPS Call American 100 30 BATO 2024-05-17
O:JSPR240517C00025000 OCASPS Call American 100 25 BATO 2024-05-17
O:JSPR240517C00022500 OCASPS Call American 100 22.5 BATO 2024-05-17
O:JSPR240517C00020000 OCASPS Call American 100 20 BATO 2024-05-17
O:JSPR240517C00017500 OCASPS Call American 100 17.5 BATO 2024-05-17
O:JSPR240517C00015000 OCASPS Call American 100 15 BATO 2024-05-17
O:JSPR240517C00012500 OCASPS Call American 100 12.5 BATO 2024-05-17
O:JSPR240419P00040000 OPASPS Put American 100 40 BATO 2024-04-19
O:JSPR240419P00035000 OPASPS Put American 100 35 BATO 2024-04-19
O:JSPR240419P00030000 OPASPS Put American 100 30 BATO 2024-04-19
O:JSPR240419C00040000 OCASPS Call American 100 40 BATO 2024-04-19
O:JSPR240419C00035000 OCASPS Call American 100 35 BATO 2024-04-19
O:JSPR240419C00030000 OCASPS Call American 100 30 BATO 2024-04-19
O:JSPR240419P00025000 OPASPS Put American 100 25 BATO 2024-04-19
O:JSPR240419P00022500 OPASPS Put American 100 22.5 BATO 2024-04-19
O:JSPR240419P00020000 OPASPS Put American 100 20 BATO 2024-04-19
O:JSPR240419P00017500 OPASPS Put American 100 17.5 BATO 2024-04-19
O:JSPR240419P00015000 OPASPS Put American 100 15 BATO 2024-04-19
O:JSPR240419P00012500 OPASPS Put American 100 12.5 BATO 2024-04-19
O:JSPR240419P00010000 OPASPS Put American 100 10 BATO 2024-04-19
O:JSPR240419C00025000 OCASPS Call American 100 25 BATO 2024-04-19
O:JSPR240419C00022500 OCASPS Call American 100 22.5 BATO 2024-04-19
O:JSPR240419C00020000 OCASPS Call American 100 20 BATO 2024-04-19
O:JSPR240419C00017500 OCASPS Call American 100 17.5 BATO 2024-04-19
O:JSPR240419C00015000 OCASPS Call American 100 15 BATO 2024-04-19
O:JSPR240419C00012500 OCASPS Call American 100 12.5 BATO 2024-04-19
O:JSPR240419C00010000 OCASPS Call American 100 10 BATO 2024-04-19
O:JSPR1240419P00007500 OPASPN Put American 10 7.5 BATO 2024-04-19
O:JSPR1240419P00005000 OPASPN Put American 10 5 BATO 2024-04-19
O:JSPR1240419P00002500 OPASPN Put American 10 2.5 BATO 2024-04-19
O:JSPR1240419C00007500 OCASPN Call American 10 7.5 BATO 2024-04-19
O:JSPR1240419C00005000 OCASPN Call American 10 5 BATO 2024-04-19
O:JSPR1240419C00002500 OCASPN Call American 10 2.5 BATO 2024-04-19
O:JSPR240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:JSPR240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:JSPR240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:JSPR240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:JSPR240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:JSPR240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:JSPR240315P00025000 OPASPS Put American 100 25 BATO 2024-03-15
O:JSPR240315P00040000 OPASPS Put American 100 40 BATO 2024-03-15
O:JSPR240315P00035000 OPASPS Put American 100 35 BATO 2024-03-15
O:JSPR240315P00022500 OPASPS Put American 100 22.5 BATO 2024-03-15
O:JSPR240315P00030000 OPASPS Put American 100 30 BATO 2024-03-15
O:JSPR240315P00020000 OPASPS Put American 100 20 BATO 2024-03-15
O:JSPR240315C00040000 OCASPS Call American 100 40 BATO 2024-03-15
O:JSPR240315P00017500 OPASPS Put American 100 17.5 BATO 2024-03-15
O:JSPR240315C00035000 OCASPS Call American 100 35 BATO 2024-03-15
O:JSPR240315P00015000 OPASPS Put American 100 15 BATO 2024-03-15
O:JSPR240315C00030000 OCASPS Call American 100 30 BATO 2024-03-15
O:JSPR240315P00012500 OPASPS Put American 100 12.5 BATO 2024-03-15
O:JSPR240315P00010000 OPASPS Put American 100 10 BATO 2024-03-15
O:JSPR240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:JSPR240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:JSPR240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:JSPR240315C00025000 OCASPS Call American 100 25 BATO 2024-03-15
O:JSPR240315C00022500 OCASPS Call American 100 22.5 BATO 2024-03-15
O:JSPR240315C00020000 OCASPS Call American 100 20 BATO 2024-03-15
O:JSPR240315C00017500 OCASPS Call American 100 17.5 BATO 2024-03-15
O:JSPR240315C00015000 OCASPS Call American 100 15 BATO 2024-03-15
O:JSPR240315C00012500 OCASPS Call American 100 12.5 BATO 2024-03-15
O:JSPR240315C00010000 OCASPS Call American 100 10 BATO 2024-03-15
O:JSPR240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:JSPR240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:JSPR240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:JSPR240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:JSPR240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:JSPR240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:JSPR240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:JSPR240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:JSPR240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:JSPR240216P00025000 OPASPS Put American 100 25 BATO 2024-02-16
O:JSPR240216P00022500 OPASPS Put American 100 22.5 BATO 2024-02-16
O:JSPR240216P00020000 OPASPS Put American 100 20 BATO 2024-02-16
O:JSPR240216P00017500 OPASPS Put American 100 17.5 BATO 2024-02-16
O:JSPR240216P00015000 OPASPS Put American 100 15 BATO 2024-02-16
O:JSPR240216P00012500 OPASPS Put American 100 12.5 BATO 2024-02-16
O:JSPR240216P00010000 OPASPS Put American 100 10 BATO 2024-02-16
O:JSPR240216C00012500 OCASPS Call American 100 12.5 BATO 2024-02-16
O:JSPR240216C00025000 OCASPS Call American 100 25 BATO 2024-02-16
O:JSPR240216C00010000 OCASPS Call American 100 10 BATO 2024-02-16
O:JSPR240216C00022500 OCASPS Call American 100 22.5 BATO 2024-02-16
O:JSPR1240216P00007500 OPASPN Put American 10 7.5 BATO 2024-02-16
O:JSPR1240216P00005000 OPASPN Put American 10 5 BATO 2024-02-16
O:JSPR240216C00020000 OCASPS Call American 100 20 BATO 2024-02-16
O:JSPR1240216P00002500 OPASPN Put American 10 2.5 BATO 2024-02-16
O:JSPR1240216C00007500 OCASPN Call American 10 7.5 BATO 2024-02-16
O:JSPR240216C00017500 OCASPS Call American 100 17.5 BATO 2024-02-16
O:JSPR1240216C00005000 OCASPN Call American 10 5 BATO 2024-02-16
O:JSPR1240216C00002500 OCASPN Call American 10 2.5 BATO 2024-02-16
O:JSPR240216C00015000 OCASPS Call American 100 15 BATO 2024-02-16
O:JSPR240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:JSPR240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:JSPR240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:JSPR240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:JSPR240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:JSPR240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:JSPR240119P00012500 OPASPS Put American 100 12.5 BATO 2024-01-19
O:JSPR240119P00010000 OPASPS Put American 100 10 BATO 2024-01-19
O:JSPR240119C00012500 OCASPS Call American 100 12.5 BATO 2024-01-19
O:JSPR240119C00010000 OCASPS Call American 100 10 BATO 2024-01-19
O:JSPR1240119P00007500 OPASPN Put American 10 7.5 BATO 2024-01-19
O:JSPR1240119P00005000 OPASPN Put American 10 5 BATO 2024-01-19
O:JSPR1240119P00002500 OPASPN Put American 10 2.5 BATO 2024-01-19
O:JSPR1240119C00007500 OCASPN Call American 10 7.5 BATO 2024-01-19
O:JSPR1240119C00005000 OCASPN Call American 10 5 BATO 2024-01-19
O:JSPR1240119C00002500 OCASPN Call American 10 2.5 BATO 2024-01-19
O:JSPR231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:JSPR231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:JSPR231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:JSPR231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:JSPR231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:JSPR231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:JSPR231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:JSPR231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:JSPR231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:JSPR231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:JSPR231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:JSPR231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:JSPR231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:JSPR231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:JSPR231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:JSPR231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:JSPR231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:JSPR231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:JSPR230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:JSPR230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:JSPR230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:JSPR230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:JSPR230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:JSPR230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:JSPR230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:JSPR230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:JSPR230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:JSPR230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:JSPR230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:JSPR230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
News Stream
Stocks Earnings Releases and Operating Results
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced results for the fiscal quarter ended March 31, 2024, and reported recent corporate developments.
GlobeNewswire Inc. • 5d ago
Health Health
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
REDWOOD CITY, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced the expansion of its mast cell development portfolio with a Phase 1b/2a study evaluating briquilimab in asthma patients that is expected to begin enrolling in the fourth quarter of 2024.
GlobeNewswire Inc. • 6d ago
Calendar Calendar of Events
Jasper Therapeutics to Present at Upcoming Investor Conferences in May
REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the following upcoming investor conferences in May:
GlobeNewswire Inc. • 1w ago
Calendar Calendar of Events
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the 23rd Annual Needham Virtual Healthcare Conference at 11am EDT on April 8, 2024.
GlobeNewswire Inc. • 1mo ago
News News
Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's Why
Jasper Therapeutics (JSPR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Zacks Investment Research • 1mo ago
Calendar Calendar of Events
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference at 10am EST on March 28, 2024.
GlobeNewswire Inc. • 1mo ago
News Clinical Study
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that the first patient has been dosed in Jasper’s Phase 1b/2a (SPOTLIGHT) clinical study of subcutaneous briquilimab for the treatment of CIndU. The SPOTLIGHT study is evaluating a single administration, at two different dose levels, of subcutaneous briquilimab in adult patients with cold urticaria (ColdU) or symptomatic dermographism (SD).
GlobeNewswire Inc. • 2mo ago
Health Health
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
REDWOOD CITY, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), announced additional positive Phase 1b/2a data on briquilimab as a conditioning agent in the treatment of Fanconi Anemia (FA).
GlobeNewswire Inc. • 2mo ago
News News
Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should Know
Does Jasper Therapeutics, Inc. (JSPR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research • 2mo ago
News News
Here's Why Momentum in Jasper Therapeutics, Inc. (JSPR) Should Keep going
Jasper Therapeutics, Inc. (JSPR) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Zacks Investment Research • 2mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT